Skip to main content
SpringerLink
Log in

PEG-Adenosine Deaminase and PEG-Asparaginase

  • Chapter
Polymer Drugs in the Clinical Stage

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 519))

Conclusions

Because of its extended blood circulating life, fewer injections of smaller amounts of Oncaspar than unmodified asparaginases are required to maintain blood asparagine levels at low, therapeutically effective levels. While immune responses do occur with Oncaspar they are fewer than with unmodified asparaginases. Oncaspar might be even more effective if given in the first level of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abuchowski, A., van Es, T., Palczuk, N.C., and Davis, F.F., 1977, Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252: 3578–3581.

    PubMed  CAS  Google Scholar 

  2. Abuchowski, A., McCoy, J.R., Palczuk, N.C., and Davis, F.F., 1977, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252: 3582–3586.

    PubMed  CAS  Google Scholar 

  3. Liu, K-J., and Parsons, J.L., 1969, Solution effects on the preferred conformation of poly(ethylene) glycols. Macromol. 2: 529–533.

    CAS  Google Scholar 

  4. Giblett, E.R., Anderson, J.E., Cohen, F., Pollara, B., and Meuwissen, H.J., 1972, Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067–1069.

    PubMed  CAS  Google Scholar 

  5. Benveniste, P., and Cohen, A., 1995, p53 expression is required for thymocyte apoptosis induced by adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA 92: 8373–9377.

    PubMed  CAS  Google Scholar 

  6. Davis, S., Abuchowski, A., Park, Y.A., and Davis, F.F., 1981, Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol. Clin. Exp. Immunol. 46: 649–652.

    PubMed  CAS  Google Scholar 

  7. Abuchowski, A., Kazo, G.M. Verhoest, Jr., C.R., van Es, T., Kafkewitz, D., Nucci, M.L., Viau, A.T. and Davis, F.F., 1984, Cancer therapy with chemically modified enzymes. 1. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7: 175–186.

    PubMed  CAS  Google Scholar 

  8. Hershfield, M., Buckley, R.H., Greenberg, M.L., Melton, A.L., Schiff, R., Hatem, C., Kurtzberg, J., Markert, M.L., Kobayashi, R.H., Kobayashi, A.L., Abuchowski, A., 1987, Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. New Eng. J. Med.. 310: 589–586.

    Google Scholar 

  9. Aiuti, A. Slavin, S. Aker, M. Ficara, S., et al., 2001, Correction of ADA-SCID defect without PEG-ADA therapy by stem/progenitor cell gene therapy combined with nonmyeloablative conditioning. Blood 98: 780a.

    Google Scholar 

  10. Hershfield, M., 1997, Biochemistry and immunology of poly(ethylene glycol)-modified adenosine deaminase (PEG-ADA). In Poly(ethyleneglycol) Chemistry and Biological Applications (J. M. Harris and S. Zalipsky, eds.), ACS symposium series, 145–154.

    Google Scholar 

  11. Hirschhorn, R., 1993, Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediat. Res. 33:Suppl., S35–41.

    PubMed  CAS  Google Scholar 

  12. Broome J.D. 1961, Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. Nature, 191: 1114–1115.

    CAS  Google Scholar 

  13. Kidd, J.G. 1953 Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum. J. Exp. Med. 98: 565–582.

    PubMed  CAS  Google Scholar 

  14. Campbell, H.A., Mashburn, L.T., Boyse, E.A., and Old, L.J., 1967, Two L-asparaginases from Escherichia coli B. Their separation, purification, and antitumor activity. Biochem. 6: 721–729.

    CAS  Google Scholar 

  15. Kurtzberg, J., 2000, Asparaginase. In Holland-Frei Cancer Medicine e. 5(R. C. Bast, Jr., et al., eds.) B.C. Decker, Inc., Hamilton, Ontario, Canada, pp. 699–705.

    Google Scholar 

  16. Abuchowski, A., Kazo, G., Verhoest, Jr., C.R., van Es, T., Kafkewitz. D., Nucci, M.L., Viau, A.T., and Davis, F.F. 1984, Cancer therapy with chemically modified enzymes.I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7: 175–186.

    PubMed  CAS  Google Scholar 

  17. Ho, D.H., Brown, N.S., Yen, A., Holmes, R., Keating, M., Abuchowski, A., Newman, R.A., and Krakoff, I.H., 1986, Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab. Dispos. 14: 349–352.

    PubMed  CAS  Google Scholar 

  18. Ho, D.S.W., Wang, C., Lin, J.R., Brown, N., Newman, R.A., Krakoff, I.H., 1988, Polyethylene glycol-L-asparaginase and L-asparaginase studies in rabbits. Drug Metab. Dispos. 16: 27–29.

    PubMed  CAS  Google Scholar 

  19. MacEwen, E.G., Rosenthal, R., Matus, R., Viau, A.T., Abuchowski, A., A preliminary study on the evaluation of asparaginase. Cancer 59: 2011–2015.

    Google Scholar 

  20. Abshire, T.C., et al., Weekly polyethylene glycol conjugated (PEG) L-asparaginase ASP) produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia (rALL): a pediatric oncology group (POG) study 9310. Proc. AM. Soc. Clin. Oncol. 14: 344.

    Google Scholar 

  21. Ettinger, L.J., Kurtzberg, J., Voute, P.A., Jurgens, H., Halpern, S.L., 1995, an open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 75: 1176–1181.

    PubMed  CAS  Google Scholar 

  22. Muss, H.B., Spell, N., Scudiery, D., Capizzi, R.L, Cooper, M.R., Cruz, J., Jackson, D.V., Richards, F., Spurr, C.L., White, R., Zekan, P.J., Franklin, A.J., 1990. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodkin’s lymphoma. Invest.New Drugs 8: 125–130.

    Article  PubMed  CAS  Google Scholar 

  23. Muller, H-J., Loning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., Schutz, V.V., Henze, G., Palma., J.C., Ritter, J., Pinhiero, J.P.V., Winkelhorst., M., Boos, J., 2000, Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br. J. Haematol. 110: 379–384.

    Article  PubMed  CAS  Google Scholar 

  24. Pinheiro, J.P.V., Muller, H.J., Schwabe, D., Gunkel, M., Palma, J.C., Henze, G., Shutz, V.V., Winkelhorst, M., Wurthwein, G., Boos, J., 2001, Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukemia. Br. J. Haematol. 113: 115–119.

    Google Scholar 

  25. Silverman, L.B., et al., 2001, Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber consortium protocol 91-01. Blood 97: 1211–1218.

    Article  PubMed  CAS  Google Scholar 

  26. Fu, C.H., Martin-Aragon, S. Weinberg, K.I., et al., 2001, Reversal of cytosine arabinoside (ARA-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEGasparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. Cancer Chemother. Pharmacol. 48: 123–133.

    Article  PubMed  CAS  Google Scholar 

  27. Taylor, C.W., Dorr, R.T., Fanta, P., et al., 2001, A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother.Pharmacol. 47: 83–88.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biotechnology Consultant, 1407 Rifle Range Road, El Cerrito, CA, 94530, USA

    Frank F. Davis

Authors
  1. Frank F. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kumamoto University School of Medicine, Kumamoto, Japan

    Hiroshi Maeda

  2. University of Nebraska Medical Center, Omaha, Nebraska

    Alexander Kabanov

  3. University of Tokyo, Tokyo, Japan

    Kazunori Kataoka

  4. Tokyo Women’s Medical College, Tokyo, Japan

    Teruo Okano

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Davis, F.F. (2004). PEG-Adenosine Deaminase and PEG-Asparaginase. In: Maeda, H., Kabanov, A., Kataoka, K., Okano, T. (eds) Polymer Drugs in the Clinical Stage. Advances in Experimental Medicine and Biology, vol 519. Springer, Boston, MA. https://doi.org/10.1007/0-306-47932-X_3

Download citation

  • DOI: https://doi.org/10.1007/0-306-47932-X_3

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-47471-2

  • Online ISBN: 978-0-306-47932-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation